Biomendex is continuing the development of its fully synthetic and biodegradable bone graft material, Adaptos, to enable better outcomes for patients and surgeons.
Currently, Biomendex is undergoing the FDA approval process for Adaptos within the spinal surgery segment in the United States. Through a recently executed know-how agreement, Biomendex will receive input from select Mayo Clinic surgeons to further advance the Adaptos product usage to new indications currently outside of the development scope.
Related: Sonablate enrols first patient in incompetent vein ablation clinical trial
“This is significant milestone for Biomendex. Through this collaboration, we can develop our technology to new healthcare segments with recognized key opinion leaders thus enabling affordable, improved patient care with easy-to-use tools. A special thanks to Business Finland as well. Their networks were used to create this dialogue in the first place,” says Pasi Kankaanpää, CEO of Biomendex.
“We look forward to working with Mayo Clinic to continue the oral and maxillofacial studies started in Finland, ultimately enabling enhanced treatment for patients,” continues Dr. Antero Salo, principal investigator of oral and maxillofacial studies of Biomendex.
Furthermore, with the support of the European Innovation Council and Business Finland, Biomendex continues to conduct an orthopedic clinical trial with the aim of obtaining marketing authorization in the EU.
The data generated will allow for further market expansion in the U.S. upon completion. Biomendex develops and manufactures a fully synthetic and biodegradable bone graft material and has received funding from both the EU Horizon program and Business Finland.
Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.
